effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.
Company profile
Ticker
EFTR
Exchange
Website
CEO
Steve Worland
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Locust Walk Acquisition Corp.
SEC CIK
Corporate docs
IRS number
853306396
EFTR stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
424B3
Prospectus supplement
4 Apr 24
8-K
Other Events
4 Apr 24
424B5
Prospectus supplement for primary offering
4 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
POS AM
Prospectus update (post-effective amendment)
29 Mar 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
2023 Financial Results and Provides Corporate Update
25 Mar 24
8-K
Other Events
30 Jan 24
Latest ownership filings
4
Caroline M Loewy
21 Feb 24
4
Elizabeth Bhatt
21 Feb 24
4
Christopher B Ehrlich
21 Feb 24
4
Barbara Klencke
21 Feb 24
4
Kristen Harrington-Smith
21 Feb 24
4
Brian M. Jr. Gallagher
21 Feb 24
4
Michael Byrnes
21 Feb 24
4
Douglas J Warner
21 Feb 24
4
STEPHEN T WORLAND
21 Feb 24
SC 13G/A
PFIZER INC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.39 mm | 5.39 mm | 5.39 mm | 5.39 mm | 5.39 mm | 5.39 mm |
Cash burn (monthly) | 3.11 mm | 543.08 k | 2.62 mm | 2.83 mm | 2.59 mm | 2.56 mm |
Cash used (since last report) | 20.66 mm | 3.61 mm | 17.40 mm | 18.81 mm | 17.18 mm | 17.03 mm |
Cash remaining | -15.27 mm | 1.78 mm | -12.01 mm | -13.42 mm | -11.79 mm | -11.65 mm |
Runway (months of cash) | -4.9 | 3.3 | -4.6 | -4.7 | -4.6 | -4.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 30 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 14.06 bn |
Total shares | 39.42 mm |
Total puts | 0.00 |
Total calls | 100.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SR One Capital Management | 6.82 mm | $56.49 mm |
SR One Capital Management | 6.82 mm | $4.03 bn |
CG Carlyle Group Inc | 4.82 mm | $2.87 bn |
Column Group Ii | 4.09 mm | $3.83 mm |
Column | 4.03 mm | $2.42 bn |
Altitude Life Science Ventures Fund II | 2.83 mm | $47.99 mm |
Sectoral Asset Management | 2.38 mm | $1.43 bn |
PFE Pfizer | 2.24 mm | $0.00 |
Parallel Advisors | 1.69 mm | $1.02 bn |
BX Blackstone | 1.31 mm | $785.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Nov 23 | SR One Capital Management | Common Stock | Sell | Dispose S | Yes | No | 0.6065 | 178,585 | 108.31 k | 1,821,415 |
27 Nov 23 | SR One Capital Management | Common Stock | Sell | Dispose S | Yes | No | 0.6065 | 430,578 | 261.15 k | 4,391,536 |
15 Nov 23 | Michael Byrnes | Common Stock | Grant | Acquire A | No | No | 0.4973 | 4,524 | 2.25 k | 43,271 |
15 Nov 23 | Worland Stephen T | Common Stock | Grant | Acquire A | No | No | 0.4973 | 5,979 | 2.97 k | 267,204 |
9 Sep 23 | Loewy Caroline M | Stock Option Common Stock | Grant | Acquire A | No | No | 0.646 | 40,000 | 25.84 k | 40,000 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
5 Apr 24
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
4 Apr 24
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
4 Apr 24
Press releases
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
4 Apr 24
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
5 Feb 24
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
29 Jan 24
Thinking about buying stock in LAVA Therapeutics, UP Fintech Holding, Babcock & Wilcox Enterprises, Safety Shot, or eFFECTOR Therapeutics?
25 Jan 24